Karyopharm Therapeutics Inc. (44) | Human Resources (22)
Browse by Subcategory
Recent Contracts
-
Amendment #1 to Consulting Agreement, dated March 21, 2022, between the Registrant and Jatin Shah
(Filed With SEC on May 5, 2022)
-
Severance Agreement, dated February 18, 2022, between the Registrant and Jatin Shah
(Filed With SEC on May 5, 2022)
-
Transition Agreement, dated March 28, 2022, between the Company and Sharon Shacham
(Filed With SEC on March 29, 2022)
-
Form of Restricted Stock Unit Agreement under 2022 Inducement Stock Incentive Plan
(Filed With SEC on March 1, 2022)
-
Non-Employee Director Compensation Policy, dated as of May 12, 2021
(Filed With SEC on August 5, 2021)
-
Retention Agreement dated January 17, 2019, between the Company and Cameron Peters
(Filed With SEC on January 18, 2019)
-
Separation Agreement dated January 17, 2019, between the Company and Michael Falvey
(Filed With SEC on January 18, 2019)
-
Consulting Agreement, dated March 1, 2022, between the Registrant and Jatin Shah
(Filed With SEC on May 5, 2022)
-
Transition Agreement, dated March 28, 2022, between the Company and Michael G. Kauffman
(Filed With SEC on March 29, 2022)
-
Form of Nonstatutory Stock Option Agreement under 2022 Inducement Stock Incentive Plan
(Filed With SEC on March 1, 2022)
-
2022 Inducement Stock Incentive Plan
(Filed With SEC on March 1, 2022)
-
Form of Restricted Stock Unit Agreement under 2013 Stock Incentive Plan adopted January 24, 2022
(Filed With SEC on March 1, 2022)
-
Form of Restricted Stock Unit Agreement under 2020 Israeli Equity Incentive Sub Plan to the 2013 Stock Incentive Plan
(Filed With SEC on November 2, 2020)
-
Form of Option Agreement under 2020 Israeli Equity Incentive Sub Plan to the 2013 Stock Incentive Plan
(Filed With SEC on November 2, 2020)
-
2020 Israeli Equity Incentive Sub Plan to the 2013 Stock Incentive Plan
(Filed With SEC on November 2, 2020)
-
Form of Restricted Stock Unit Agreement under 2013 Stock Incentive Plan adopted August 25, 2020
(Filed With SEC on November 2, 2020)
-
Form of Nonstatutory Stock Option Agreement under 2013 Stock Incentive Plan adopted August 25, 2020
(Filed With SEC on November 2, 2020)
-
Form of Incentive Stock Option Agreement under 2013 Stock Incentive Plan adopted August 25, 2020
(Filed With SEC on November 2, 2020)
-
Consulting Agreement, dated as of September 25, 2020, between the Company and Christopher B. Primiano
(Filed With SEC on September 25, 2020)
-
Transition Agreement, dated as of September 25, 2020, between the Company and Christopher B. Primiano
(Filed With SEC on September 25, 2020)
-
Karyopharm Therapeutics Inc. Annual Bonus Plan
(Filed With SEC on August 6, 2019)
-
Consulting Agreement dated January 18, 2019, between the Company and Michael Falvey
(Filed With SEC on January 18, 2019)